Antidepressant-induced mania: An overview of current controversies

Bipolar Disorders

Volumn 5, Issue 6, 2003, Pages 407-420

  Goldberg, Joseph F ^a   Truman, Christine J ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Antidepressant drugs; Antidepressant induced mania; Bipolar disorder; Mania; Mood stabilizers

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE;

ADOLESCENCE; ADULTHOOD; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG USE; FAMILY HISTORY; GENETIC LOAD; HUMAN; HYPOMANIA; MANIA; MEDICAL LITERATURE; MEDLINE; MENTAL INSTABILITY; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AFFECT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DISEASE SUSCEPTIBILITY; DRUG THERAPY, COMBINATION; FEMALE; FORECASTING; HUMANS; MALE; PRACTICE GUIDELINES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0346025644     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-5618.2003.00067.x     Document Type: Review

References (99)

1. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987; 144: 1403-1411.
2. Wehr TA, Goodwin FK. Rapid cycling between mania and depression caused by maintenance tricyclics. Psychopharmacol Bull 1979; 15: 17-19.
3. Moller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000; 57-68.
4. Goodwin FK, Jamison KR. Manic Depressive Illness. New York: Oxford University Press, 1999.
5. Altshuler LL, Post RM, Leverich GS et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152: 1130-1138.
6. Boerlin HL, Gitlin MJ, Zoellner LA et al. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry 1998; 59: 374-379.
7. Henry C, Sorbara F, Lacoste J et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001; 62: 249-255.
8. Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 2002; 63: 791-795.
9. Truman CJ, Baldassano CF, Goldberg JF et al. History of antidepressant-induced mania in the STEP 500. New research poster #29 presented at the 156th Annual Meeting of the American Psychiatric Association, May 17-22, 2003, San Francisco, CA.
10. Lewis JL, Winokur G. The induction of mania: a natural history study with controls. Arch Gen Psychiatry 1982; 39: 303-306.
11. Roy-Byrne P, Post RM, Uhde TW et al. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 1985; 317: 1-34.
12. Krauthammer C, Klerman GL. Secondary mania: manic syndromes associated with antecedent physical illness or drugs. Arch Gen Psychiatry 1978; 35: 1333-1339.
13. Evans DL, Byerly MJ, Greer RA. Secondary mania: diagnosis and treatment. J Clin Psychiatry 1995; 56 (Suppl. 3): 1-7.
14. Knudson AG Jr. Genetic predisposition to cancer. Cancer Detect Prev 1984; 7: 1-8.
15. Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987; 144: 201-204.
16. Katz G, Knobler HY, Laibel Z et al. Time zone change and major psychiatric morbidity: the results of a 6-year study in Jerusalem. Compr Psychiatry 2002; 43: 37-40.
17. Tay LK, Dunner DL. A report on three patients with "rapid cycling" unipolar depression. Compr Psychiatry 1992; 33: 253-255.
18. Post RM, Rubinow DR, Ballenger JC. Conditioning and sensitization in the longitudinal course of affective illness. Br J Psychiatry 1986; 149: 191-201.
19. Ghaemi SN, Boiman EE, Goodwin FK. Kindling and second messengers: an approach to the neurobiology of recurrence in bipolar disorder. Biol Psychiatry 1999; 45: 137-144.
20. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. J Nerv Ment Dis 1994; 182: 349-352.
21. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives caused by tricyclic antidepressants. Arch Gen Psychiatry 1979; 36: 555-559.
22. Goldstein TR, Frye MA, Denicoff KD et al. Antidepressant discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder. J Clin Psychiatry 1999; 60: 563-567.
23. Henry C. Reply to Drs Gabbay O'Dowd and Asnis (letter). J Clin Psychiatry 2002; 63: 367-368.
24. Dilsaver SC, Greden JF. Antidepressant withdrawal-induced activation (hypomania and mania): mechanism and theoretical implications. Brain Res Rev 1984; 7: 29-48.
25. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58: 291-297.
26. Tsuang MT, Faraone SV, Fleming JA. Familial transmission of major affective disorders. Is there evidence supporting the distinction between unipolar and bipolar disorders? Br J Psychiatry 1985; 146: 268-271.
27. Akiskal HS, Downs J, Jordan P et al. Affective disorders in referred children and younger siblings of manic-depressives. Model of onset and prospective course. Arch Gen Psychiatry 1985; 42: 996-1003.
28. Blacker D, Lavori PW, Faraone SV et al. Unipolar relatives in bipolar pedigrees: a search for indicators of underlying bipolarity. Am J Med Genet 1993; 48: 192-199.
29. Klerman GL. The classification of bipolar disorders. Psych Ann 1987; 17: 13-17.
30. Blacker D, Tsuang MT. Contested boundaries of bipolar disorder and the limits of categorical diagnosis in psychiatry. Am J Psychiatry 1992; 149: 1473-1483.
31. Schatzberg A, Dessian E, O'Neil P et al. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. J Clin Psychopharmacol 1987; 7: 44S-49S.
32. Levy D, Kimhi R, Barak Y et al. Antidepressant-associated mania: a study of anxiety disorder patients. Psychopharmacology 1998; 136: 243-246.
33. Vieta E, Bernardo M. Antidepressant-induced mania in obsessive-compulsive disorder (letter). Am J Psychiatry 1992; 149: 1282-1283.
34. Berk M, Koopowitz LF, Szabo CP. Antidepressant induced mania in obsessive compulsive disorder. Eur Neuro-psychopharmacol 1996; 6: 9-11.
35. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 2002; 68: 1-23.
36. Perugi G, Micheli C, Akiskal HS et al. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Compr Psychiatry 2002; 41: 13-18.
37. Dunner DL, Fleiss JL, Fieve RR. The course of development of mania in patients with recurrent depression. Am J Psychiatry 1976; 133: 905-908.
38. Bunney WE. Psychopharmacology of the switch process in affective illness. In: Lipton MA, DiMascio A, Killam KF, eds. Psychopharmacology: A Generation of Progress. New York: Raven Press, 1978: 1249-1259.
39. Angst J. Switch from depression to mania: a record study over decades between 1920 and 1982. Psychopathology 1985; 18: 140-154.
40. Coryell W, Endicott J, Maser JD et al. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995; 152: 385-390.
41. Rao AV, Nammalvar N. The course and outcome in depressive illness: a follow-up study of 122 cases in Madurai, India. Br J Psychiatry 1977; 130: 392-396.
42. Perugi G, Akiskal HS, Lattanzi L et al. The high prevalence of "soft" bipolar (II) features in atypical depression. Compr Psychiatry 1998; 39: 63-71.
43. Akiskal HS, Maser JD, Zeller PJ et al. Switching from "unipolar" to bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 1995; 52: 114-123.
44. Mendels J. Lithium in the treatment of depression. Am J Psychiatry 1976; 133: 373-378.
45. DePue RA, Monroe SM. The unipolar-bipolar distinction in the depressive disorders. Psychol Bull 1978; 85: 1001-1029.
46. Cassano GB, Musetti L, Perugi G et al. A proposed new approach to the clinical subclassification of depressive illness. Pharmacopsychiatry 1988; 21: 19-23.
47. Cassano GB, Akiskal HS, Musetti L et al. Psychopathology, temperament, and past course in primary major depressions. 2. Toward a redefinition of bipolarity with a new semistructured interview for depression. Psychopathology 1989; 22: 278-288
48. Akiskal HS, Walker P, Puzantian VR et al. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. J Affect Disord 1983; 5: 115-128.
49. Akiskal HS. Development of pathways to bipolarity: are juvenile-onset depressions pre-bipolar? J Am Acad Child Adolesc Psychiatry 1995; 34: 754-763.
50. Geller B, Zimerman B, Williams M et al. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry 2001; 158: 125-127.
51. Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry 1982; 39: 549-555.
52. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adol Psych 1996; 35: 705-715.
53. McInnis MG, McMahon FJ, Chase GA et al. Anticipation in bipolar affective disorder. Am J Hum Genetics 1993; 53: 385-390.
54. Alda M, Grof P, Ravindran L et al. Anticipation in bipolar affective disorder: is age at onset a valid criterion? Am J Med Genet 2000; 96: 804-807.
55. Visscher PM, Yazdi MH, Jackson AD et al. Genetic survival analysis of age-at-onset of bipolar disorder; evidence for anticipation or cohort effect in families. Psychiatric Genet 2001; 11: 129-137.
56. Swann AC, Janicak PL, Calabrese JR et al. Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants. J Affect Disord 2001; 67: 123-132.
57. Benazzi F. Age of onset of bipolar II depressive mixed state. Psych Res 2001; 103: 229-235.
58. Meeks S. Bipolar disorder in the latter half of life: symptom presentation, global functioning and age of onset. J Affect Disord 1999; 52: 161-167.
59. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry 2002; 63: 985-991.
60. McElroy SL, Altshuler LL, Suppes T et al. Axis I comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420-426.
61. Pini S, Dell'Osso L, Mastrocinque C et al. Axis I comorbidity in bipolar disorder with psychotic features. Br J Psychiatry 1999; 175: 467-471.
62. Schurhoff F, Bellivier F, Jouvent R et al. Early and late onset bipolar disorders: two different forms of manic-depressive illness? J Affect Disord 2000; 58: 215-221.
63. Sugurdsson E, Fombonne E, Sayal K et al. Neurodevelopmental antecedents of early-onset bipolar affective disorder. Br J Psychiatry 1999; 174: 121-127.
64. Roy A. Family history of suicide in affective disorder patients. J Clin Psychiatry 1985; 46: 317-319.
65. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994; 31: 91-96.
66. Tohen M, Hennen J, Zarate CM Jr et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000; 157: 220-228.
67. Amsterdam JD, Garcia-Espana F, Fawcett J et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18: 435-440.
68. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18: 414-417.
69. Mundo E, Walker M, Cate T et al. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001; 58: 539-544.
70. Baldassano CF, Sachs GS, Stoll AL et al. Paroxetine for bipolar depression: outcome in patients failing prior antidepressant trials. Depression 1995; 3: 182-186.
71. Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry 1992; 53: 443-446.
72. Stoll AL, Mayer PV, Kolbrener M et al. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry 1994; 151: 1642-1645.
73. Howland RH. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996; 16: 425-427.
74. Preda A, MacLean RW, Mazure CM et al. Antidepressant-associated mania and psychosis resulting in psychiatric admissions. J Clin Psychiatry 2001; 62: 30-33.
75. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549-550.
76. Barak Y, Kimhi R, Weizman R. Is selectivity for serotonin reuptake associated with a reduced emergence of manic episodes in depressed patients? Int Clin Psychopharmacol 2000; 5: 53-56.
77. Himmelhoch JM, Thase ME, Mallinger AG et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916.
78. Post RM, Altshuler LL, Frye MA et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001; 3: 259-265.
79. Gabbay V, O'Dowd MA, Asnis GM. Combined antidepressant treatment: a risk factor for switching in bipolar patients (letter). J Clin Psychiatry 2002; 63: 367.
80. Zubieta JK, Demitrack MA. Possible bupropion precipitation of mania and a mixed affective state. J Clin Psychopharmacol 1991; 11: 327-328.
81. Sachs GS, Printz DJ, Kahn DA et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder. Postgrad Med 2000; 1: 1-104.
82. Sachs GS, Lafer B, Stoll AL et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-393.
83. Nemeroff CB, Evans DL, Gyulai L et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906-912.
84. Young LT, Joffe RT, Robb JC et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar disorder. Am J Psychiatry 2000; 157: 124-126.
85. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand 2001; 104: 104-109.
86. Jann MW, Bitar AH, Rao A. Lithium prophylaxis of tricyclic-antidepressant-induced mania in bipolar patients. Am J Psychiatry 1982; 139: 683-684.
87. Bottlender R, Rudolf D, Strauß A et al. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001; 63: 79-84.
88. Stoner SC, Worel JA, Vlach D et al. Retrospective analysis of serum valproate levels and need for an antidepressant drug. Pharmacotherapy 2001; 21: 850-854.
89. Wehr TA, Sack DA, Rosenthal NE et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 179-184.
90. MacQueen GM, Trevor Young L, Marriott M et al. Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatr Scand 2002; 105: 414-418.
91. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry 2002; 159 (Suppl. 4): 1-50.
92. Erfurth A, Michael N, Stadland C et al. Bupropion as add-in strategy in difficult-to-treat bipolar depressive disorder. Neuropsychobiology 2002; 45 (Suppl. 1): 33-36.
93. Thase ME, Mallinger AG, McKnight D et al. Treatment of imipramine-resistant recurrent depressions, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-198.
94. Vieta E, Martinez-Aran A, Goikolea JM. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63: 508-512.
95. Kupfer DJ, Chengappa KNR, Gelenberg AJ et al. Citalopram as adjunctive therapy in bipolar depression. J Clin Psychiatry 2001; 62: 985-990.
96. Kupfer DJ, Chengappa KNR, Gelenberg AJ et al. Citalopram treatment of bipolar depression. Poster presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 10-14, 2000.
97. Cohn JB, Collins G, Ashbrook E et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-322.
98. Hantouche EG, Akiskal HS, Lancrenon S et al. Systematic clinical methodology for validating bipolar II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord 1998; 50: 163-173.
99. Nasrallah HA, Lyskowski J, Schroeder D. TCA-induced mania: differences between switchers and nonswitchers. Biol Psychiatry 1982; 17: 271-274.